Understand the source comparison
Tesofensine Stack: Comparison
Tesofensine + Tirzepatide Non-overlapping (monoamine vs GLP-1 receptor) Low. No shared pathways Tesofensine AM, Tirzepatide weekly Weekly BP/HR for first month Safe stack. Additive fat loss through independent mechanisms Tesofensine + CJC-1295/Ipamorelin Non-o
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Tesofensine + Tirzepatide
- Non-overlapping (monoamine vs GLP-1 receptor)
- Low. No shared pathways
- Tesofensine AM, Tirzepatide weekly
- Weekly BP/HR for first month
- Safe stack. Additive fat loss through independent mechanisms
- Tesofensine + CJC-1295/Ipamorelin
- Non-overlapping (monoamine vs GHRH receptor)
- Low. No CNS interaction
- Tesofensine AM, GH secretagogue PM
- Baseline and monthly IGF-1, fasting glucose
- Safe stack. GH-mediated lipolysis complements central appetite suppression
- Tesofensine + DMAA or stimulants
- Overlapping (both affect NE signalling)
- High. Synergistic sympathetic activation
- Never combine
- Continuous ECG if accidental co-administration
- Dangerous. Cardiovascular events documented
- Tesofensine + SSRIs/SNRIs
- Overlapping (serotonin reuptake inhibition)
- High. Serotonin syndrome risk
- Requires dose adjustment or cessation
- Daily mental status checks, core temp monitoring
- Contraindicated without prescriber oversight
- Tesofensine + AOD-9604
- Non-overlapping (monoamine vs lipolytic enzyme)
- Minimal. Peripheral vs central action
- Both can be dosed AM
- Standard BP/HR monitoring
- Safe stack. No receptor overlap